Becky Freeman and the Policing of the Nicotine Debate

https://www.theguardian.com/business/2026/feb/26/public-health-advocates-say-more-transparency-needed-in-debate-over-illicit-tobacco-as-industry-links-questioned

Following on from my last Substack about The Guardian and Melissa Davey, Becky Freeman’s comments in the article reveal more than perhaps she intended. They lay bare a worldview in which disagreement is not a matter of evidence but of alignment, and where certain policy questions are treated as inherently illegitimate because of who else happens to ask them.

Freeman claims that the tobacco industry has long argued that tighter regulation fuels illicit trade and that this argument has “never been backed by evidence.” That is an extraordinary statement. It is not merely scepticism. It is dismissal. The relationship between price shocks and black market growth is one of the most studied dynamics in economics and criminology. When legal supply becomes dramatically more expensive than illicit alternatives, arbitrage incentives expand. This is not tobacco industry doctrine. It is basic market behaviour.

To suggest that there is no evidence that tax escalation can contribute to illicit trade is to ignore decades of scholarship across alcohol, fuel, pharmaceuticals, and narcotics policy. It is also to ignore contemporary Australian reality. Law enforcement agencies have publicly acknowledged the growth of illicit tobacco networks. Seizure volumes have surged. Violent turf conflicts linked to illegal supply chains have made national headlines. None of this proves that excise is the sole driver, but it makes categorical denial untenable.

Freeman’s second claim is more revealing. She argues that the industry has shifted strategy away from health and toward crime, gangs, and law enforcement. This framing is clever because it reframes the reframing. It implies that the crime discussion itself is artificial, a communications tactic rather than a policy consequence.

But crime did not enter the conversation because of the public relations strategy. It entered because there is crime. When shops are firebombed, and illicit products openly circulate in suburbs, the debate will inevitably expand beyond epidemiology into enforcement. Suggesting that this expansion is merely a strategic repositioning subtly delegitimises anyone who speaks about the impacts of crime.

Freeman then goes further, warning that industry-aligned spokespeople can appear as neutral crime experts while promoting commercially convenient policies. This assertion carries a serious implication. It suggests that professionals who emphasise enforcement realities are not genuinely concerned with criminal markets but are functioning as vehicles for industry messaging.

That is not a policy critique. It is an accusation of motive.

There is a pattern here. The focus is not on modelling the elasticity of demand under extreme excise settings. It is not about presenting alternative data about the illicit market size. It is not on demonstrating that tax increases are still delivering net harm reduction without significant displacement effects. Instead, the focus is on casting suspicion on those who raise uncomfortable questions.

Freeman insists that transparency is the bare minimum and that anyone advising or working with industry bodies should disclose those relationships. On the surface, this is uncontroversial. Transparency is important. But the principle only has integrity if it is universal.

Do public health academics who receive government funding tied to explicit endgame strategies reiterate that funding source every time they appear in the media? Do advocacy groups disclose philanthropic backers with defined anti-nicotine agendas in every public comment? Do researchers collaborating with campaign organisations preface each quote with a statement of institutional alignment?

If transparency is invoked selectively, it becomes less about informing the public and more about constructing a hierarchy of legitimacy.

Freeman’s framing also narrows the concept of harm. By insisting the debate should remain centred on health and resisting the shift toward crime, she implicitly treats enforcement consequences as peripheral. Yet organised crime is not external to public health. Violence, resource diversion, community intimidation, and lost revenue all have downstream social effects. A policy that reduces smoking prevalence but significantly expands criminal enterprise raises legitimate questions about balance.

The more troubling element is the rhetorical certainty. To say that the illicit trade argument has “never been backed by evidence” leaves no room for nuance. It implies that the question has been conclusively settled. Yet markets are dynamic. Threshold effects exist. Policies that were effective at one tax level may produce different outcomes at another. Refusing to entertain that possibility is not scientific confidence. It is ideological entrenchment.

There is a philosophical divide at play. One view holds that regulatory intensity should continue escalating because any retreat risks normalising nicotine use. The other view holds that beyond a certain point, marginal health gains may be offset by criminal displacement and consumer substitution into unregulated channels. That is a legitimate debate in public policy. It appears in drug reform, alcohol taxation, and gambling regulation. It is not inherently corrupt to raise it.

Freeman’s comments suggest that raising it is suspect because of who else might benefit from the answer.

That logic is dangerous. If a policy concern is invalid simply because a commercial actor also expresses it, then public debate becomes a purity test. Arguments are judged not by evidence but by adjacency.

Australia’s nicotine policy environment is under visible strain. Smoking declines have slowed in some cohorts. Illicit tobacco visibility has increased. Enforcement responses are intensifying. Alternative product demand persists despite bans. These realities demand open examination. They do not demand rhetorical containment.

Freeman is right about one thing. Transparency is important. But intellectual transparency is just as critical as financial disclosure. It requires acknowledging uncertainty, admitting trade-offs, and engaging opposing arguments on their merits rather than attributing them to strategy.

When the response to enforcement-based critiques is to imply that the crime discussion itself is a corporate pivot, the debate shifts from data to motive. That shift may protect a preferred narrative, but it does not strengthen public health policy.

The real test is empirical. Are illicit markets expanding? Are excise increases approaching diminishing returns? Would regulated alternatives reduce black market demand? Those questions can be answered with evidence.

What they cannot answer is the assertion that raising them is inherently industry reframing.